BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Bio-path Holdings, Inc. BPTH
15 fiscal years on record · USD · FY2024 reported · SEC filings only
$-9.9M
Growth
—
Revenue, FY2024 · full 15-year series below
Revenue $M
Net income $M
FY2018 · Revenue 0.0 · Net income -8.6
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2017 · Operating -24232.4% · Net -18981.1%
ROE
FY2024 · ROE -3325.7%
Each USD of equity lost 3326 cents this year.
The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | −0.0 | −0.0 | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| EPS, diluted $ | −4.12 | −33.63 | −38.12 | −1.55 | −2.83 | −3.24 | −14.38 | −15.99 | −0.73 | −0.06 | −0.05 | −0.05 | −0.04 | −0.04 | −0.04 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −3325.7 | −220.0 | −70.0 | −51.5 | −60.2 | −77.1 | −184.9 | −86.1 | −74.8 | −44.2 | −45.9 | −96.1 | −104.8 | −81.8 | −72.7 |
| Shares out B | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.09 | 0.08 | 0.06 | 0.06 | 0.05 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 61 reconciliationsAUDITED
Reconciled in 17 of 19 fiscal years. 15 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inWyoming
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007